Publicaciones en las que colabora con Akdis Mübeccel (41)

2023

  1. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 11, pp. 2851-2874

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

  3. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs

    Nature Reviews Drug Discovery, Vol. 22, Núm. 9, pp. 743-767

2022

  1. Cannabinoid WIN55212-2 impairs peanut-allergic sensitization and promotes the generation of allergen-specific regulatory T cells

    Clinical and Experimental Allergy, Vol. 52, Núm. 4, pp. 540-549

  2. Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming

    Mucosal Immunology, Vol. 15, Núm. 1, pp. 96-108

  3. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 1, pp. 17-38

  4. Mechanismen bei AIT: Erkenntnisse 2021

    Allergologie, Vol. 45, Núm. 12, pp. 848-856

  5. The cannabinoid WIN55212-2 suppresses effector T-cell responses and promotes regulatory T cells in human tonsils

    Allergy: European Journal of Allergy and Clinical Immunology

2021

  1. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  2. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 988-1009

  3. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 45-58

  4. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353

  5. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 59-70

  6. Persistent human bocavirus 1 infection and tonsillar immune responses

    Clinical and Translational Allergy, Vol. 11, Núm. 6

  7. The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption

    Allergy: European Journal of Allergy and Clinical Immunology

  8. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 6, pp. 1640-1660

2020

  1. A compendium answering 150 questions on COVID-19 and SARS-CoV-2

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2503-2541

  2. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  3. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057